Medicine News and Research

RSS

GSK-3alpha protein: A potent, positive regulator of cardiac hypertrophy

A protein long thought to be a secondary regulator in the heart's response to stressors like hypertension actually appears to be a primary regulator according to researchers from the Center for Translational Medicine at Thomas Jefferson University.

17 Nov 2009

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

Mount Sinai School of Medicine is one of 12 sites nationwide participating in the first Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease. The study is the first multicenter neurosurgical intervention in Alzheimer's research in the U.S.

17 Nov 2009

NIH awards $3 million grant to ASU professors for research on rapid DNA sequencing technology

Arizona State University has been awarded nearly $3 million in federal stimulus funds from the National Institutes of Health. ASU professors Stuart Lindsay and Paul Westerhoff will lead a pair of two-year, innovative projects designed to tackle challenges in the fields of rapid DNA sequencing and the potential health risks of nanotechnology.

17 Nov 2009

Implementing infection-limiting measures a challenge, say researchers

The H1N1 flu virus is spreading misery around the country, but University of Michigan researchers say that implementing and sustaining infection-limiting measures will still be a challenge.

16 Nov 2009

NIH grant to establish East African Center of Excellence in Health Informatics

A $1.3 million grant to Indiana University from the National Institutes of Health's Fogarty International Center will establish the East African Center of Excellence in Health Informatics.

16 Nov 2009

Los Angeles Times examines health care in Sierra Leone

The Los Angeles Times writes: "Sierra Leone is one of those nations where decades of foreign aid have failed to appreciably lift the fortunes of the people. The country is a charity case: 60% of its public spending comes from foreign governments and nonprofit organizations.

16 Nov 2009

SynerMed and L.A. Care team up to launch e-consult program

SynerMed, Inc., the largest Medicaid managed service organization (MSO) in the country, in collaboration with L.A. Care Health Plan, the nation’s largest public health plan, announced today the launch of an e-consult pilot program.

16 Nov 2009

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).

16 Nov 2009

Scientists develop new technique to measure brain volume loss for monitoring of Alzheimer's disease

In a study that promises to improve diagnosis and monitoring of Alzheimer's disease, scientists at the University of California, San Diego have developed a fast and accurate method for quantifying subtle, sub-regional brain volume loss using magnetic resonance imaging (MRI). The study will be published the week of November 16 in the Proceedings of the National Academy of Sciences (PNAS).

16 Nov 2009

Determining the cause for death of photoreceptors could hold the key to stopping blinding disorders

Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science.

16 Nov 2009

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.

16 Nov 2009

Migraine headaches linked with increased risk of common kind of stroke

Pooling results from 21 studies, involving 622,381 men and women, researchers at Johns Hopkins have affirmed that migraine headaches are associated with more than twofold higher chances of the most common kind of stroke: those occurring when blood supply to the brain is suddenly cut off by the buildup of plaque or a blood clot.

16 Nov 2009

Electronic health records not yet making impact, patients turn to web for advice

As the United States launches "an ambitious program, backed by $19 billion in government incentives, to accelerate the adoption of computerized patient records in doctors' offices and hospitals," a new study of 3,000 hospitals "has found little difference in the cost and quality of care," The New York Times reports.

16 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

Today's opinions and editorials

Many liberals remain angry and disappointed that single-payer legislation never stood a chance in Washington. To them, a government-run health-care system seemed an obvious way to put patients ahead of profits. But a single-payer system would have put us at the mercy of whomever happened to take control of Washington (Maggie Mahar, 11/15).

16 Nov 2009

China Medicine reports total revenues of $19.2M for the third quarter of 2009

China Medicine Corporation, a developer and a leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations, today announced its third quarter 2009 results.

16 Nov 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.

16 Nov 2009

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA.

16 Nov 2009

SANUWAVE Health reports financial results for the three months ended September 30, 2009

SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports its achievements and financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Medicine News and Research

GSK-3alpha protein: A potent, positive regulator of cardiac hypertrophy

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

NIH awards $3 million grant to ASU professors for research on rapid DNA sequencing technology

Implementing infection-limiting measures a challenge, say researchers

NIH grant to establish East African Center of Excellence in Health Informatics

Los Angeles Times examines health care in Sierra Leone

SynerMed and L.A. Care team up to launch e-consult program

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

Scientists develop new technique to measure brain volume loss for monitoring of Alzheimer's disease

Determining the cause for death of photoreceptors could hold the key to stopping blinding disorders

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Migraine headaches linked with increased risk of common kind of stroke

Electronic health records not yet making impact, patients turn to web for advice

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Today's opinions and editorials

China Medicine reports total revenues of $19.2M for the third quarter of 2009

Fate Therapeutics announces the completion of $30 million Series B financing

FDA approves Lysteda for treating menorrhagia

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

SANUWAVE Health reports financial results for the three months ended September 30, 2009

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News